Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis D

Background & Aims: Portal hypertension (PH) drives decompensation in patients with advanced chronic liver disease. Effects of antiviral treatment with bulevirtide (BLV) and achievement of suggested treatment endpoints on PH in patients with chronic hepatitis D (CHD) are unknown. Methods: BLV-tre...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Lisa Sandmann, Mathias Jachs, Tammo L. Tergast, Lukas Hartl, Birgit Bremer, Martin A. Kabelitz, Michael Schwarz, Julius F.M. Egge, Lorenz Balcar, Benedikt Silvester Hofer, Christine S. Falk, Albert Friedrich Stättermayer, Markus Cornberg, Michael Trauner, Katja Deterding, Mattias Mandorfer, Heiner Wedemeyer, Thomas Reiberger, Benjamin Maasoumy
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-01-01
coleção:	JHEP Reports
Assuntos:	HDV CSPH HVPG Viral hepatitis
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2589555925003258
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!